The Hidden Chemistry Problem: Why Peptide Impurities and Immunogenicity Drive FDA Caution

Regulators treat many peptides as higher-risk than typical small-molecule drugs because peptide chemistry invites two problems that aspirin never poses: the manufacturing process leaves behind closely related impurities, and the immune system can recognize a peptide, or its impurities, as foreign. When the body raises antibodies against a peptide drug, the medicine can stop working or, less often, provoke a reaction. Add the aggregation that large, flexible molecules undergo and the sterility demands of injection, and you have the scientific reasons behind cautious oversight.

A peptide is not a small molecule

A conventional drug like ibuprofen is a small, rigid molecule with a handful of atoms arranged one way. A peptide is a short chain of amino acids, the same building blocks proteins are made of. That size and biological familiarity are exactly what make peptides useful, and exactly what make them harder to control. A chain assembled one amino acid at a time can go wrong at any step, and the immune system, evolved to inspect protein fragments, has machinery ready to notice the difference.

This is why the regulatory questions for peptides look less like those for a simple pill and more like those for a biologic. The chemistry is intermediate, and so is the risk profile.

The impurity problem

Making a peptide by chemical synthesis is a repetitive coupling reaction, and every cycle can produce a slightly wrong product. The result is a family of impurities that resemble the intended molecule closely enough to be hard to remove: sequences missing an amino acid, sequences with an extra one, oxidized or deamidated side chains, and racemized residues where the molecular handedness has flipped. A peer-reviewed 2024 analysis in Frontiers in Pharmacology examining salmon calcitonin catalogued roughly twenty such synthesis-related impurities, spanning deletions, insertions, side-chain modifications, and incomplete removal of protecting groups.

The concern is not that impurities exist. Every drug has them. The concern is that a peptide impurity can carry a new sequence the parent drug does not, and that new sequence can behave like a foreign flag to the immune system. FDA's thinking here is explicit. Its guidance on abbreviated applications for certain highly purified synthetic peptides directs applicants to identify and characterize any impurity present above 0.10 percent of the active ingredient and to compare that profile against the reference product. The guidance goes further for genuinely new impurities, treating those appearing at higher levels as a potential immunogenicity risk that the agency believes an abbreviated application cannot adequately resolve. The threshold is low because the stakes are biological, not merely cosmetic.

Why immunogenicity is the central worry

Immunogenicity means the drug triggers an immune response against itself. The immune system samples protein fragments, displays them, and, if a fragment looks foreign enough, mounts a response that includes anti-drug antibodies. For a peptide medicine, those antibodies can neutralize the drug, shorten how long it lasts, or in some cases contribute to adverse effects.

The salmon calcitonin work illustrates the scale of the problem for a susceptible peptide. A large fraction of treated patients develop anti-drug antibodies over time, and many develop neutralizing antibodies that blunt the drug's effect. The 2024 study's contribution was to show, using computational and laboratory methods, that specific impurities carrying modifications at immune-facing positions could raise the immunogenic risk above that of the parent molecule. In other words, a manufacturing byproduct present at a fraction of a percent can change how the immune system reacts to the whole product, so it deserves scrutiny well beyond a routine purity check.

Aggregation and sterility

Two further properties push peptides toward stricter handling. Peptides and proteins can aggregate, clumping into higher-order structures, and aggregates are among the strongest known drivers of unwanted immune responses. A solution that looks fine can carry aggregated material that the immune system treats as a danger signal. Controlling aggregation across manufacturing, shipping, and storage is a real formulation challenge, not a solved problem.

The second is sterility. Most peptides that matter clinically are injected, because the digestive tract would break them down if swallowed. Any injectable made without validated sterile process controls carries infection and particulate risk regardless of the molecule inside it. That is a manufacturing-quality concern layered on top of the chemistry.

What this means for regulatory categories

These scientific facts explain why the legal status of a peptide matters so much, and why the categories are worth keeping straight. An FDA-approved peptide medicine has been through characterization, impurity control, immunogenicity assessment, and sterile manufacturing review. A compounded preparation and a research-only chemical have not cleared that same bar. Under section 503A of the federal compounding law, FDA has placed a number of peptide substances into a category reserved for bulk ingredients that raise significant safety concerns, citing immunogenicity, peptide-related impurities, difficulty characterizing the active ingredient, and thin human safety data.

The categories shift over time, and it is easy to misread a procedural step as a verdict. When FDA in 2026 moved to remove a set of peptides from that significant-concern category, the change did not approve them, did not place them on the permitted compounding list, and did not resolve the underlying chemistry. As the agency and outside analysts have noted, an advisory committee recommendation is non-binding, and formal notice-and-comment rulemaking would still be required before any such substance could be lawfully compounded under 503A. FDA-approved, compounded, and research-only remain distinct legal states, and the distance between them tracks the very impurity and immunogenicity questions described here. This article is educational and is not medical advice.